The Un-official Maricann Investor Page (CSE:MARI, OTC:MRRCF)
Legal Disclaimer: Do not take anything stated below as investment advice. Always do your own due diligence.
Fully Diluted Share Count: 182,344,440
Estimated Market Cap: $309,985,548 CAD
State-of-the-art Langton Facility
Maricann's GMP certified facility in Langton, Ontario is currently undertaking an expansion of its cultivation in a 942,000 sq. ft. (87,515 sq. m) build out, capable of producing over 105,000kg of dry cannabis flower per year. Construction is on going 19 hours a day (7 a.m-2 a.m) and is anticipated to be completed by mid-2019.
Once completed the facility is to be fully automated. With the partnership of Fortune 500 company Rockwell Automation (NYSE:ROK) for approximately one million square feet of cultivation Maricann only expects to require 20-25 people for labour. Some competitors operating out of similar sized facilities require 200-300+ people for labour. With these cost saving initiatives cost per gram is estimated to be well under $1, making Maricann an excellent contender as the lowest cost producer of cannabis.
By mid-November, 2018 Maricann expects to be capable of producing 706kg of dried cannabis per week (36,712kg per annum) in Phase 1 of the expansion. By April 2019, it expects to be capable of producing 2,023kg of dried cannabis per week (105,196kg per annum).
Maricann's Langton facility is designed to achieve from 88 percent to net zero efficiency which means that the vast majority of the facility is expected to generate no carbon emissions. The facility also houses a fully self contained energy system that recycles all the water on site including even the gutters that collect rain water. This eco-friendly design is good for the environment and also attributes in lowering the overall cost of production.
http://thedeepdive.ca/maricann-group-super-low-cost-producer/
VESIsorb
A proven pharmaceutical technology, VESIsorb allows extracts of both THC and CBD to be effectively incorporated into beverages, edibles, capsules and transdermal products, addressing the needs of both the medicinal and recreational markets. By enhancing bioavailability, VESIsorb technology reduces the onset time of cannabinoids from 60 to 90 minutes, to 10 to 15 minutes. It also makes it much easier for doctors to prescribe and administer precise doses to patients. It is rumored that the reason $30B market cap pharmaceutical company McKesson (NYSE:MCK) partnered with Maricann was to get access to this exclusive patented technology.
Maricann, through the acquisition of NanoLeaf, has the exclusive rights to use VESIsorb with cannabis products in Canada, Europe, South America (excluding Uruguay), Israel and Australia. Maricann also obtained certain non-exclusive rights for the rest of the world (excluding the United States), and certain states within the United States.
In June of 2018, Maricann announced that it has received its EudraCT (European Union Drug Regulating Authority Clinical Trial) number and Protocol Code Number for its pharmacokinetic study to examine the potential increase in bioavailability of cannabinoids. Maricann expects to commence clinical trial studies under the leadership of Dr. Markus Backmund.
PubMed articles referencing VESIsorb in non-cannabis application:
Haxxon AG/CBD Cigarettes
Acquired by Maricann in May of 2018, Haxxon operates within a 64,500 sq. ft. (6,000 sq. m.) indoor facility in Regensdorf, Switzerland producing 100% hemp cigarettes.
These products are 100% legal complying with both Swiss and European law with THC below 1% for the local market and THC below 0.2% for the broader European market.
Maricann is seen as having first mover advantage in this niche, up and coming industry. As more health conscious consumers seek out tobacco alternatives, this is seen as a very compelling growth market for Maricann.
Ben Ward during a Reddit AMA stated '"One competitor in the nascent industry is doing 1.4 MM CHF ($1.88M CAD) per month... and it's brand new, lots of room to expand."
Maricann has partnered with Amsterdam Cannabis Cup winner Rare Dankess genetics to make these cigarettes. They will also come in Maricann's recreational brand "Kiwi".
Coming to market late 2018 in Switzerland.
German Operations
Maricann, through its subsidiary Maricann GmbH, owns a 820,000 sq. ft GMP and GPP compliant facility located in Ebersbach, Germany that is currently retrofitted for 86,111 sq. ft (8,000 sq. m) of cannabis grow space. Maricann’s joint venture partner has submitted bid documents for the German government's tender process for regulated cannabis, following qualification in the first round of such process as one of 10 successful applicants to move forward (of 118 applicants in total). This is required for Maricann to grow cannabis in Germany. As this process is still on going, Maricann's current plan is to export the cannabis grown at its GMP certified Langton facility into Germany.
Mariplant GmbH, a subsidiary of Maricann, planted 405 acres (164 hectares) of hemp on April 18, 2018 in Saxony, Germany. By comparing it to a competitors estimated revenue, and before being converted into value added products such as CBD cigarettes or VESIsorb CBD pills, this is estimated to generate Maricann $33,750,000 a year in revenue.
